Offering financing to improve the standard of care.

Elekta facts

  • 750,000 oncology treatments
    Through Elekta and other manufacturer partners, DLL-equipment equipment performs 750,000 oncology treatments annually.
  • Best possible care
    The mission of the medical professionals at the ARTC is to offer every patient the best possible care, regardless of geographic location.
  • Access to Elekta technology
    Patients who had to travel to receive treatment, have access to Elekta technology within Alaska’s 586,000 miles of rugged terrain.

Making cutting edge medical technology available

State-of-the-art radiation services are easier to come by if you are in a major city or academic center—but what about in Anchorage, Alaska? For Richard Chung, M.D., and his team of medical professionals at the Anchorage Radiation Therapy Center (ARTC), they make it their mission to offer every patient the best possible care regardless of geographic location. That is why the acquisition of the Elekta Leskell Gamma Knife®, for use in brain stereostatic radiosurgery (SRS)  was so important to him.

ARTC previously operated two linear accelerators, one of which is an Elekta Synergy® system, and with these two systems treated cancer in a variety of anatomical sites. Next they added the capability to perform stereotactic body radiotherapy.

“The one thing we were lacking was the ability to treat intracranial targets with the highest precision,” said Richard Chung, MD, ARTC Medical Director. “The addition of Perfexion has been very complementary to the scope of our practice, and has helped avoid sending patients out of state.”

…and then making the technology affordable

Among brain SRS technology choices, clinicians at ARTC selected Leksell Gamma Knife Perfexion for its speed and gold standard accuracy, and because it’s a system dedicated to intracranial targets. To achieve this treatment goal, ARTC partnered with DLL on the purchase.  

“We offered a financing solution to Dr. Chung and his associates, in order to better allocate their capital budget, and ultimately improve the standard of care,” said Ian Dickson, Chief Financial Officer  at Elekta.

“DLL stands apart from their competitors, because of their extensive knowledge of the dynamic healthcare environment and commitment to achieving our business goals.



DLL’s commitment to oncology

DLL understands the difference that putting the right equipment in the right hands can mean for patients.

“Treatment options for a patient with metastatic cancer—especially when the cancer has travelled to the brain—are limited,” said Amy Nelson, President, Global Healthcare Business Unit, DLL. “We are so proud to work with Elekta, who is pioneering significant innovations and clinical solutions for treating cancer and brain disorders.”

Now patients who formerly had to travel to the continental U.S. to receive treatment,  have access to Elekta technology within Alaska’s 586,000 miles of rugged terrain.

Through Elekta and other manufacturer partners, DLL-financed equipment performs 750,000 oncology treatments annually.

Innovation

The world is constantly changing, and that is probably no where more evident than in the U.S. healthcare marketplace. “DLL makes it their business to stay on top of major healthcare trends so that together we can evolve to remain successful—serving our customers in a way that makes sense today, while preparing for the future,” said Dickson at Elekta. “By having their finger on the pulse of our industry, we can together address the growing financing needs of physicians and hospitals.”

“While Elekta continues to stretch the boundaries of science and technology we will be right their alongside them to deliver innovative financial options to increase availability for patients,” said Nelson.

Ian Dickson

Chief Financial Officer at Elekta

“DLL makes it their business to stay on top of major healthcare trends so that together we can evolve to remain successful—serving our customers in a way that makes sense today, while preparing for the future.”